SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, has sold the commercial rights to its thrombosis business in Europe to US-based Mylan for €641.9m , and will use the funds to further reduce its debt, it announced on Tuesday.
Investors welcomed the news, sending its shares up as much as 9.4% during intraday trading before closing 5.42% up at R141.33. The company has a market capitalisation of R64.5bn.A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.
Loans Loans Latest News, Loans Loans Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Aspen sells European thrombosis business to MylanThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Source: BDliveSA - 🏆 12. / 63 Read more »
Aspen to sell European thrombosis business for €641.9mThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Source: BDliveSA - 🏆 12. / 63 Read more »
Aspen sells European thrombosis business to MylanThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Source: BDliveSA - 🏆 12. / 63 Read more »
Aspen to sell European thrombosis business for €641.9mThe proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says
Source: BDliveSA - 🏆 12. / 63 Read more »